<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:department>Dept of Surgery and Cancer</gtr:department><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2512972D-6FE3-48FC-8B6B-CBD2BA6CE18A"><gtr:id>2512972D-6FE3-48FC-8B6B-CBD2BA6CE18A</gtr:id><gtr:name>Missouri University of Science and Tech</gtr:name><gtr:address><gtr:line1>Missouri University of Science and Tech</gtr:line1><gtr:line2>1870 Miner Circle</gtr:line2><gtr:line4>Rolla</gtr:line4><gtr:line5>Missouri</gtr:line5><gtr:postCode>MO 65409</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/B65641A9-867C-4B89-AE58-C1D272F8A45E"><gtr:id>B65641A9-867C-4B89-AE58-C1D272F8A45E</gtr:id><gtr:firstName>Jonathan</gtr:firstName><gtr:surname>Krell</gtr:surname><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G1100425"><gtr:id>B0AFE16E-F463-4972-9DD8-097CDE172774</gtr:id><gtr:title>The regulation of microRNA (miRNA) biogenesis and the role of miRNA binding proteins in breast cancer.</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G1100425</gtr:grantReference><gtr:abstractText>MicroRNAs are a newly discovered class of molecules that act as genetic regulators within cells. They control processes involved in cell division and cell death, and have important roles in preventing cancer. We have found that estrogen (a major regulator in breast cancer,) causes production of specific microRNAs. These microRNAs down-regulate the activity of the gene that codes for the estrogen receptor-alpha - which performs the functions of estrogen inside cells by stimulating the production of particular proteins called estrogen response elements. This means that there is never too much estrogenic activity and it is controlled, in a unique feedback loop that we have identified. In breast cancer however, the microRNAs are not properly produced, so there is no down-regulation of estrogenic activity, and the breast cancer cells continue to divide. If we can turn this process off, or give patients the microRNAs they don?t make, we can treat breast cancer and reverse this process. Firstly, we must identify the different types of microRNAs in breast cancer and understand which factors control microRNA production. This would present exciting new possibilities for diagnosis and patient-specific treatments, and may help us to detect hard-to-diagnose cancer and determine how aggressively a cancer might behave.</gtr:abstractText><gtr:technicalSummary>Aims: 
The aims of the proposed project are to establish how miRNAs are regulated by the estrogen receptor- (ER ) in breast cancer and to identify the estrogen (E2)-inducible miRNA binding proteins involved.

Objectives:
1. To investigate the clinical relevance of the mir-17-92 and mir-106a-363 family of miRNAs in breast cancer.
2. To determine the mechanism(s) by which transcription of the mir-17-92 and mir-106a-363 clusters is regulated.
3. To analyse the mechanism(s) of miRNA biogenesis in breast cancer and establish the identity of the E2-inducible factor(s) involved.

Design:
Objective 1- We will use quantitative real-time PCR to measure the expression of the primary miRNA transcripts, pre-miRNAs and mature molecules belonging to the mir-17-92 and mir-106a-363 families of miRNAs, in well characterised sets of breast cancer specimens. We will study their clinical relevance by investigating whether these ER -regulated miRNAs correlate to outcomes, including survival, comparing ER -positive and ER -negative tumours. 
Objective 2- We will identify ER /ER -modulated transcription factor binding sites upstream/ downstream of the mir-17-92 and 106a-363 transcriptional start sites using the UCSC genome browser and ChIP analyses prior to/following E2 stimulation. We will use chromosome capture assays to assess whether promoter and enhancer sequences are components of the same chromatin regions of identified interaction sites, and to identify the genomic localisation of the promoters/enhancers for the miRNA transcripts. The biological relevance of any regulatory binding will be investigated using siRNA knockdown of transcription factors and luciferase reporter assays. 
Objective 3- We will utilise model systems to establish the identity of the estrogen-inducible factor(s) causing inhibition of miRNA processing and determine the contribution of post-transcriptional miRNA regulation in response to ER , to oncogenesis.

Methodology
The proposed project uses a range of cell and molecular biology techniques, bioinformatics and tissue handling techniques, which are well established in the host laboratory. 

Scientific and Medical Opportunities
Based on previous data, we hypothesise that post-transcriptional regulation is a general mechanism of miRNA biogenesis with relevance to breast cancer, and that an estrogen-inducible mechanism is responsible for the inhibition of miRNA processing. We aim to demonstrate the involvement of miRNA binding factors in this process, and implicate them as potential new therapeutic targets. This also has general relevance to oncology, as miRNAs are major regulators of the development and growth of many cancers, although the associated mechanisms remain poorly understood. Finally, this research will increase our knowledge of the potential role of miRNAs as biomarkers in breast cancer.</gtr:technicalSummary><gtr:fund><gtr:end>2014-08-29</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2012-01-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>202378</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>EBFB0F56-4B00-48D4-AFA9-356F50058C04</gtr:id><gtr:title>The role of miR-10b in metastatic pancreatic ductal adenocarcinoma.</gtr:title><gtr:parentPublicationTitle>Surgery</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/acaf30a8186ef9eb97059a8c8aaae958"><gtr:id>acaf30a8186ef9eb97059a8c8aaae958</gtr:id><gtr:otherNames>Frampton AE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0039-6060</gtr:issn><gtr:outcomeId>5460a90163ca37.99518256</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D2ABDD53-C580-45BF-9C2C-0C2081052FDD</gtr:id><gtr:title>The prognostic role of circulating tumor cells in heavily pretreated individuals with a low life expectancy.</gtr:title><gtr:parentPublicationTitle>Future oncology (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2e33acbcfebc59f56dcd3f5a93527f83"><gtr:id>2e33acbcfebc59f56dcd3f5a93527f83</gtr:id><gtr:otherNames>Stebbing J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1479-6694</gtr:issn><gtr:outcomeId>5460a8ba661669.64286948</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F66958CB-E33C-4966-8A6E-51EFF3D0DECB</gtr:id><gtr:title>The p53 miRNA interactome and its potential role in the cancer clinic.</gtr:title><gtr:parentPublicationTitle>Epigenomics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5030cde49f5b6dba14f2ed66b8a6ce6f"><gtr:id>5030cde49f5b6dba14f2ed66b8a6ce6f</gtr:id><gtr:otherNames>Krell J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1750-192X</gtr:issn><gtr:outcomeId>5460a902ec1497.54288200</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>05F0FE86-C79C-46B0-AF25-4E3D37E5D54F</gtr:id><gtr:title>Broader implications of a stage-guided stratified therapeutic approach for AIDS-related Kaposi's sarcoma.</gtr:title><gtr:parentPublicationTitle>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5030cde49f5b6dba14f2ed66b8a6ce6f"><gtr:id>5030cde49f5b6dba14f2ed66b8a6ce6f</gtr:id><gtr:otherNames>Krell J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0732-183X</gtr:issn><gtr:outcomeId>5460a903e94af6.58064940</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C2591930-DF76-4C27-96BF-92ACF898D17C</gtr:id><gtr:title>Response to sunitinib (Sutent) in chemotherapy refractory clear cell ovarian cancer.</gtr:title><gtr:parentPublicationTitle>Gynecologic oncology reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0072a8b59f829e2a3ee857b59b860b94"><gtr:id>0072a8b59f829e2a3ee857b59b860b94</gtr:id><gtr:otherNames>Alifrangis C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2352-5789</gtr:issn><gtr:outcomeId>5a9fa0d17eb681.22596499</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E31A39BD-61E2-4DB9-ACB0-DDB4C6ACF97C</gtr:id><gtr:title>Distinct miRNA profiles are associated with malignant transformation of pancreatic cystic tumors revealing potential biomarkers for clinical use.</gtr:title><gtr:parentPublicationTitle>Expert review of molecular diagnostics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/acaf30a8186ef9eb97059a8c8aaae958"><gtr:id>acaf30a8186ef9eb97059a8c8aaae958</gtr:id><gtr:otherNames>Frampton AE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1473-7159</gtr:issn><gtr:outcomeId>5460a902a52c40.76544857</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>46A609FE-4312-43B9-AF2B-7CD2B3BF026D</gtr:id><gtr:title>The Clinico-Pathologic Role of MicroRNAs miR-9 and miR-151-5p in Breast Cancer Metastasis</gtr:title><gtr:parentPublicationTitle>Molecular Diagnosis &amp; Therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5030cde49f5b6dba14f2ed66b8a6ce6f"><gtr:id>5030cde49f5b6dba14f2ed66b8a6ce6f</gtr:id><gtr:otherNames>Krell J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:outcomeId>5a6ef25b8315c3.29928633</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D9C305E1-853F-4575-82A3-54F7CDF0EDA1</gtr:id><gtr:title>Towards a clinical use of miRNAs in pancreatic cancer biopsies.</gtr:title><gtr:parentPublicationTitle>Expert review of molecular diagnostics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/acaf30a8186ef9eb97059a8c8aaae958"><gtr:id>acaf30a8186ef9eb97059a8c8aaae958</gtr:id><gtr:otherNames>Frampton AE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1473-7159</gtr:issn><gtr:outcomeId>5460a901d91655.08057051</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F9EF0ABA-D83A-411E-9F74-F1248AA922D8</gtr:id><gtr:title>Sustained expression of miR-26a promotes chromosomal instability and tumorigenesis through regulation of CHFR.</gtr:title><gtr:parentPublicationTitle>Nucleic acids research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4b561b16674dd7979a4ded077046f14e"><gtr:id>4b561b16674dd7979a4ded077046f14e</gtr:id><gtr:otherNames>Castellano L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0305-1048</gtr:issn><gtr:outcomeId>5a9fa0d14648a8.37589701</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DF93E67A-DE11-4464-B779-23AFC0B364A5</gtr:id><gtr:title>Emerging roles of competing endogenous RNAs in cancer: insights from the regulation of PTEN.</gtr:title><gtr:parentPublicationTitle>Molecular and cellular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1f2bef4bfd0ffd0920fad8c50ac105d0"><gtr:id>1f2bef4bfd0ffd0920fad8c50ac105d0</gtr:id><gtr:otherNames>de Giorgio A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0270-7306</gtr:issn><gtr:outcomeId>5460a903223e59.84164086</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>496B587F-615A-411F-A3DC-BFCA00777889</gtr:id><gtr:title>Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data.</gtr:title><gtr:parentPublicationTitle>The Lancet. Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d05daabad545c7a6de6f4dd795c479f8"><gtr:id>d05daabad545c7a6de6f4dd795c479f8</gtr:id><gtr:otherNames>Bidard FC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1470-2045</gtr:issn><gtr:outcomeId>5460a90437d7b9.66459741</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D8B297FE-8252-4F1D-83AF-E23BF5BEB2E0</gtr:id><gtr:title>miR-23b regulates cytoskeletal remodeling, motility and metastasis by directly targeting multiple transcripts.</gtr:title><gtr:parentPublicationTitle>Nucleic acids research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7a8aaa6bcfaf29d49a0d45f2b4779252"><gtr:id>7a8aaa6bcfaf29d49a0d45f2b4779252</gtr:id><gtr:otherNames>Pellegrino L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0305-1048</gtr:issn><gtr:outcomeId>5460a902827c07.97084472</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AF75D2A6-B90B-4087-A349-7359AF865674</gtr:id><gtr:title>The clinico-pathologic role of microRNAs miR-9 and miR-151-5p in breast cancer metastasis.</gtr:title><gtr:parentPublicationTitle>Molecular diagnosis &amp; therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5030cde49f5b6dba14f2ed66b8a6ce6f"><gtr:id>5030cde49f5b6dba14f2ed66b8a6ce6f</gtr:id><gtr:otherNames>Krell J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1177-1062</gtr:issn><gtr:outcomeId>jq2Ko3yEjGA</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>14377792-01C6-4C8D-BE25-065D361E8D2A</gtr:id><gtr:title>Altered expression of the miRNA processing endoribonuclease Dicer has prognostic significance in human cancers.</gtr:title><gtr:parentPublicationTitle>Expert review of anticancer therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7a8aaa6bcfaf29d49a0d45f2b4779252"><gtr:id>7a8aaa6bcfaf29d49a0d45f2b4779252</gtr:id><gtr:otherNames>Pellegrino L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1473-7140</gtr:issn><gtr:outcomeId>5460a9020ace42.83492633</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CE18762C-C1D4-41D9-9818-1B27E01F75F0</gtr:id><gtr:title>Investigating miRNA-mRNA regulatory networks using crosslinking immunoprecipitation methods for biomarker and target discovery in cancer.</gtr:title><gtr:parentPublicationTitle>Expert review of molecular diagnostics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b0efd4a5a30c37baef1adc1c7d93cc6d"><gtr:id>b0efd4a5a30c37baef1adc1c7d93cc6d</gtr:id><gtr:otherNames>Mato Prado M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1473-7159</gtr:issn><gtr:outcomeId>5a9fa0d1a73988.15458502</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C0012CF2-F774-4735-A3BD-0822A127B5FB</gtr:id><gtr:title>MicroRNAs targeting oncogenes are down-regulated in pancreatic malignant transformation from benign tumors.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/df811aaba9c58927d2ab5a3781cb327b"><gtr:id>df811aaba9c58927d2ab5a3781cb327b</gtr:id><gtr:otherNames>Jiao LR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>NqW6yqiYQUs</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6046C992-77A1-4F58-B82A-55CF4F5ED436</gtr:id><gtr:title>Can pharmacogenomics guide effective anticancer therapy in pancreatic ductal adenocarcinoma?</gtr:title><gtr:parentPublicationTitle>Pharmacogenomics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5030cde49f5b6dba14f2ed66b8a6ce6f"><gtr:id>5030cde49f5b6dba14f2ed66b8a6ce6f</gtr:id><gtr:otherNames>Krell J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1462-2416</gtr:issn><gtr:outcomeId>isfPd3RWzVm</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>111F3827-957E-4194-BA32-22A0D5D1C866</gtr:id><gtr:title>Prospective validation of microRNA signatures for detecting pancreatic malignant transformation in endoscopic-ultrasound guided fine-needle aspiration biopsies.</gtr:title><gtr:parentPublicationTitle>Oncotarget</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/acaf30a8186ef9eb97059a8c8aaae958"><gtr:id>acaf30a8186ef9eb97059a8c8aaae958</gtr:id><gtr:otherNames>Frampton AE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1949-2553</gtr:issn><gtr:outcomeId>5a9fa0d1c8cb44.18763405</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B8CF4EF0-30A8-420A-9C0D-6782574A8E50</gtr:id><gtr:title>P65Myocardial miR-30 down-regulation caused by doxorubicin alters the beta-adrenergic system and mitochondrial death pathways</gtr:title><gtr:parentPublicationTitle>Cardiovascular Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/535c43fe360eeab59ce89723162feb40"><gtr:id>535c43fe360eeab59ce89723162feb40</gtr:id><gtr:otherNames>Roca-Alonso L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>5a6f05517baf62.50076484</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9347A790-1580-467F-B8DF-AD32A4379602</gtr:id><gtr:title>Circulating tumour cells as biomarkers in early breast cancer.</gtr:title><gtr:parentPublicationTitle>The Lancet. Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5030cde49f5b6dba14f2ed66b8a6ce6f"><gtr:id>5030cde49f5b6dba14f2ed66b8a6ce6f</gtr:id><gtr:otherNames>Krell J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1470-2045</gtr:issn><gtr:outcomeId>Kg4QGGi7s9k</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C89BD748-87B3-4BA5-BAF3-D4EC58F2DE49</gtr:id><gtr:title>Viable circulating tumour cell detection using multiplex RNA in situ hybridisation predicts progression-free survival in metastatic breast cancer patients.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/87370babba26c6a21953a7d58928262a"><gtr:id>87370babba26c6a21953a7d58928262a</gtr:id><gtr:otherNames>Payne RE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>ixM34CryK2y</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DFD68AF6-1DE5-4E09-B6FF-63148CB32C95</gtr:id><gtr:title>Transcriptome-level microarray expression profiling implicates IGF-1 and Wnt signalling dysregulation in the pathogenesis of thyroid-associated orbitopathy.</gtr:title><gtr:parentPublicationTitle>Journal of clinical pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/992951272fd0d9cd8c338e1cfd807dcf"><gtr:id>992951272fd0d9cd8c338e1cfd807dcf</gtr:id><gtr:otherNames>Ezra DG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0021-9746</gtr:issn><gtr:outcomeId>RZM3kh3YyCp</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C4E4155C-D59B-4DA4-B169-12157BCEE84C</gtr:id><gtr:title>Downregulation of microRNA-515-5p by the estrogen receptor modulates sphingosine kinase 1 and breast cancer cell proliferation.</gtr:title><gtr:parentPublicationTitle>Cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/51c0cc3a0d067cfafa22377624726f64"><gtr:id>51c0cc3a0d067cfafa22377624726f64</gtr:id><gtr:otherNames>Pinho FG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0008-5472</gtr:issn><gtr:outcomeId>5460a903485393.63283507</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A91BC53A-6F02-4CC1-92C5-0306F874FF1E</gtr:id><gtr:title>The &amp;quot;malignant truth&amp;quot; about the recurrence of pancreatic intraductal papillary mucinous neoplasms.</gtr:title><gtr:parentPublicationTitle>Archives of surgery (Chicago, Ill. : 1960)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/acaf30a8186ef9eb97059a8c8aaae958"><gtr:id>acaf30a8186ef9eb97059a8c8aaae958</gtr:id><gtr:otherNames>Frampton AE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0004-0010</gtr:issn><gtr:outcomeId>BGjxxcKf3rF</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>85AF646D-40A4-4FF8-97F2-2C7EF1194513</gtr:id><gtr:title>Bioinformatic analysis reveals pancreatic cancer molecular subtypes specific to the tumor and the microenvironment.</gtr:title><gtr:parentPublicationTitle>Expert review of molecular diagnostics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/537f3afc93d850a1dbf4b0b7479a104d"><gtr:id>537f3afc93d850a1dbf4b0b7479a104d</gtr:id><gtr:otherNames>Le Large TY</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1473-7159</gtr:issn><gtr:outcomeId>5a9fa0d21eb775.21318098</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>79CD69D4-4C48-4EC4-9564-77FC1BA45633</gtr:id><gtr:title>Growth arrest-specific transcript 5 associated snoRNA levels are related to p53 expression and DNA damage in colorectal cancer.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5030cde49f5b6dba14f2ed66b8a6ce6f"><gtr:id>5030cde49f5b6dba14f2ed66b8a6ce6f</gtr:id><gtr:otherNames>Krell J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>5460a8ba8d5da4.47670032</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2E9496DC-0735-4614-A982-D827C0C921E0</gtr:id><gtr:title>A Review of Thoracic and Mediastinal Cytoreductive Techniques in Advanced Ovarian Cancer: Extending the Boundaries.</gtr:title><gtr:parentPublicationTitle>Annals of surgical oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2808304c05c593ad4ee67ce04dfdc35f"><gtr:id>2808304c05c593ad4ee67ce04dfdc35f</gtr:id><gtr:otherNames>Nasser S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1068-9265</gtr:issn><gtr:outcomeId>5a9fa0d120aaa6.99475957</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F85A0E0F-9525-4266-846F-767E0918A754</gtr:id><gtr:title>Coffee: the science and art of moderation.</gtr:title><gtr:parentPublicationTitle>The Lancet. Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5030cde49f5b6dba14f2ed66b8a6ce6f"><gtr:id>5030cde49f5b6dba14f2ed66b8a6ce6f</gtr:id><gtr:otherNames>Krell J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1470-2045</gtr:issn><gtr:outcomeId>JKdKsFUPQHX</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8AF5466A-5DF8-4704-804A-C6B34D6BAAF1</gtr:id><gtr:title>Circulating molecular markers in pancreatic cancer: ready for clinical use?</gtr:title><gtr:parentPublicationTitle>Future oncology (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/631c9fb0b07866bfc1740289ce561700"><gtr:id>631c9fb0b07866bfc1740289ce561700</gtr:id><gtr:otherNames>Gall TM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1479-6694</gtr:issn><gtr:outcomeId>5460a90233e8e2.50227044</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A0E71CDB-D998-459E-AFF0-DDB5CFD5234C</gtr:id><gtr:title>Reply to S.E. Krown et al.</gtr:title><gtr:parentPublicationTitle>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5030cde49f5b6dba14f2ed66b8a6ce6f"><gtr:id>5030cde49f5b6dba14f2ed66b8a6ce6f</gtr:id><gtr:otherNames>Krell J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0732-183X</gtr:issn><gtr:outcomeId>5460a8babbdf41.51833922</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>08BF3BC5-82C8-4A3C-8CB4-7ED78F213A61</gtr:id><gtr:title>Abstract P2-08-08: Circulating tumor cells count-based nomograms to predict survival of metastatic breast cancer patients: Results from the European pooled analysis</gtr:title><gtr:parentPublicationTitle>Cancer Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7824bbcaa2807e9b68216bcf316e560a"><gtr:id>7824bbcaa2807e9b68216bcf316e560a</gtr:id><gtr:otherNames>Bidard F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:outcomeId>5a6f53642c0f47.73378019</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>52E3A984-A7BE-46E4-AE6C-6F8F38BA61FB</gtr:id><gtr:title>'Being there' for women with metastatic breast cancer: a pan-European patient survey.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d07be128b0127bb5735551c56cd8bfa8"><gtr:id>d07be128b0127bb5735551c56cd8bfa8</gtr:id><gtr:otherNames>Harding V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>5460a903927d25.65532418</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A011FD8F-1344-4841-9D76-5858C740DA2A</gtr:id><gtr:title>Assessing tumor molecular profiling to guide treatments for patients with advanced female genital tract malignancy.</gtr:title><gtr:parentPublicationTitle>Oncotarget</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c38eeb9a62a4d2dacf875d2772aa0b69"><gtr:id>c38eeb9a62a4d2dacf875d2772aa0b69</gtr:id><gtr:otherNames>Carter P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1949-2553</gtr:issn><gtr:outcomeId>5a9fa0d0df1274.84636477</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7F4F2993-DA6C-40B9-B203-3AAEED964364</gtr:id><gtr:title>Is the detection of circulating tumor cells in locally advanced pancreatic cancer a useful prognostic marker?</gtr:title><gtr:parentPublicationTitle>Expert review of molecular diagnostics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/631c9fb0b07866bfc1740289ce561700"><gtr:id>631c9fb0b07866bfc1740289ce561700</gtr:id><gtr:otherNames>Gall TM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1473-7159</gtr:issn><gtr:outcomeId>doi_13648_013_845091</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>48D88F62-2ED4-48B1-AE5F-ECF4204565F2</gtr:id><gtr:title>Defining a prognostic molecular profile for ductal adenocarcinoma of the pancreas highlights known key signaling pathways.</gtr:title><gtr:parentPublicationTitle>Expert review of anticancer therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/acaf30a8186ef9eb97059a8c8aaae958"><gtr:id>acaf30a8186ef9eb97059a8c8aaae958</gtr:id><gtr:otherNames>Frampton AE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1473-7140</gtr:issn><gtr:outcomeId>5460a901b3b731.04683124</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>47DF367D-75CE-49C5-8938-1F5040CE7AD8</gtr:id><gtr:title>MicroRNAs cooperatively inhibit a network of tumor suppressor genes to promote pancreatic tumor growth and progression.</gtr:title><gtr:parentPublicationTitle>Gastroenterology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/acaf30a8186ef9eb97059a8c8aaae958"><gtr:id>acaf30a8186ef9eb97059a8c8aaae958</gtr:id><gtr:otherNames>Frampton AE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0016-5085</gtr:issn><gtr:outcomeId>5460a903b80381.24025569</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>59761B92-30C5-4469-A6AD-5E7AC3A4297D</gtr:id><gtr:title>Secukinumab improves patient-reported psoriasis symptoms of itching, pain, and scaling: results of two phase 3, randomized, placebo-controlled clinical trials.</gtr:title><gtr:parentPublicationTitle>International journal of dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2df5a0b29c9fa62a92b39917c5b2cbb0"><gtr:id>2df5a0b29c9fa62a92b39917c5b2cbb0</gtr:id><gtr:otherNames>Strober B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0011-9059</gtr:issn><gtr:outcomeId>5a9fa0d1eb9589.31931288</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>42FEC897-9ED8-4D7A-9839-6D71460B5FCC</gtr:id><gtr:title>Blood-based miRNAs as noninvasive diagnostic and surrogative biomarkers in colorectal cancer.</gtr:title><gtr:parentPublicationTitle>Expert review of molecular diagnostics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/631c9fb0b07866bfc1740289ce561700"><gtr:id>631c9fb0b07866bfc1740289ce561700</gtr:id><gtr:otherNames>Gall TM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1473-7159</gtr:issn><gtr:outcomeId>5460a9025bb927.74867121</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4816635F-1233-4A04-BB0C-4CA8C669DAF8</gtr:id><gtr:title>Circulating peripheral blood mononuclear cells exhibit altered miRNA expression patterns in pancreatic cancer.</gtr:title><gtr:parentPublicationTitle>Expert review of molecular diagnostics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/acaf30a8186ef9eb97059a8c8aaae958"><gtr:id>acaf30a8186ef9eb97059a8c8aaae958</gtr:id><gtr:otherNames>Frampton AE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1473-7159</gtr:issn><gtr:outcomeId>5460a902c8bc43.85548948</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>343D1ED9-4FD6-42CF-8EBF-70BB901A4925</gtr:id><gtr:title>Loss of miR-126 is crucial to pancreatic cancer progression.</gtr:title><gtr:parentPublicationTitle>Expert review of anticancer therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/acaf30a8186ef9eb97059a8c8aaae958"><gtr:id>acaf30a8186ef9eb97059a8c8aaae958</gtr:id><gtr:otherNames>Frampton AE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1473-7140</gtr:issn><gtr:outcomeId>5460a9018dc6d8.89939577</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8E3322E3-EBA1-4C11-A6CB-112D20A265EB</gtr:id><gtr:title>Changing the breastfeeding conversation and our culture.</gtr:title><gtr:parentPublicationTitle>Breastfeeding medicine : the official journal of the Academy of Breastfeeding Medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5368f4237ac78a36addefbff39079c3e"><gtr:id>5368f4237ac78a36addefbff39079c3e</gtr:id><gtr:otherNames>Christopher GC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1556-8253</gtr:issn><gtr:outcomeId>5a9fa0d250c9e9.53553560</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>44C3663B-A6CF-40B2-935E-F616C6211633</gtr:id><gtr:title>Reforms in the English National Health Service: the voluntary sector in cancer care provision.</gtr:title><gtr:parentPublicationTitle>The Lancet. Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5030cde49f5b6dba14f2ed66b8a6ce6f"><gtr:id>5030cde49f5b6dba14f2ed66b8a6ce6f</gtr:id><gtr:otherNames>Krell J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1470-2045</gtr:issn><gtr:outcomeId>5460a9036c80d2.57617687</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>196730BC-1481-4A8E-9588-8F837AF9A3EC</gtr:id><gtr:title>Lymph node ratio can further stratify prognosis in subpopulations of breast cancer patients with axillary nodal metastases.</gtr:title><gtr:parentPublicationTitle>Future oncology (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2a2688e2be454ce1bde0882568d38997"><gtr:id>2a2688e2be454ce1bde0882568d38997</gtr:id><gtr:otherNames>Lawn AM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1479-6694</gtr:issn><gtr:outcomeId>doi_13648_on_13_154_</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G1100425</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>